BACKGROUND: Eight randomized controlled trials (RCTs) of screening mammography were conducted involving women ages 40 to 49 years at entry. Current data gathered for periods ranging from 7 to 18 years of follow-up are available from these trials. METHODS: Meta-analyses were performed using a Mantel-Haenszel estimator method to combine current follow-up data from the eight RCTs of mammography that included women ages 40 to 49 years. RESULTS: Combining all current data on women ages 40 to 49 years at entry into the trials yielded a 16% [corrected] benefit from screening mammography, without statistical significance at the 95% confidence level. Combining all data on women ages 40 to 49 years at entry, excluding results from the Canadian National Breast Screening Study, yielded a 24% [corrected] benefit to women invited for screening, with statistical significance at the 95% confidence level. CONCLUSIONS: These results suggest that screening mammography in women ages 40 to 49 years at entry can reduce mortality from breast cancer when combined with adequate follow-up.
BACKGROUND: Eight randomized controlled trials (RCTs) of screening mammography were conducted involving women ages 40 to 49 years at entry. Current data gathered for periods ranging from 7 to 18 years of follow-up are available from these trials. METHODS: Meta-analyses were performed using a Mantel-Haenszel estimator method to combine current follow-up data from the eight RCTs of mammography that included women ages 40 to 49 years. RESULTS: Combining all current data on women ages 40 to 49 years at entry into the trials yielded a 16% [corrected] benefit from screening mammography, without statistical significance at the 95% confidence level. Combining all data on women ages 40 to 49 years at entry, excluding results from the Canadian National Breast Screening Study, yielded a 24% [corrected] benefit to women invited for screening, with statistical significance at the 95% confidence level. CONCLUSIONS: These results suggest that screening mammography in women ages 40 to 49 years at entry can reduce mortality from breast cancer when combined with adequate follow-up.
Authors: P A Carney; M E Goodrich; D M O'Mahony; A N Tosteson; M S Eliassen; S P Poplack; S Birnbaum; B G Harwood; K A Burgess; B T Berube; W S Wells; J P Ball; M M Stevens Journal: J Community Health Date: 2000-06
Authors: Jun Wei; Berkman Sahiner; Lubomir M Hadjiiski; Heang-Ping Chan; Nicholas Petrick; Mark A Helvie; Marilyn A Roubidoux; Jun Ge; Chuan Zhou Journal: Med Phys Date: 2005-09 Impact factor: 4.071
Authors: Jun Wei; Heang-Ping Chan; Berkman Sahiner; Lubomir M Hadjiiski; Mark A Helvie; Marilyn A Roubidoux; Chuan Zhou; Jun Ge Journal: Med Phys Date: 2006-11 Impact factor: 4.071